Core Viewpoint - Metsera Inc. received an unsolicited acquisition proposal from Novo Nordisk, which it considers a "Superior Company Proposal" under its existing agreement with Pfizer [1][3] Group 1: Acquisition Proposal Details - Novo Nordisk's proposal is structured in two steps, with an initial cash payment of $56.50 per share and additional contingent value rights based on development milestones [2][7] - The total potential value of Novo Nordisk's proposal could reach up to $77.75 per share, equating to approximately $9 billion [3] Group 2: Pfizer's Response - Pfizer has acknowledged Novo Nordisk's proposal, labeling it as "reckless and unprecedented," and claims it aims to suppress competition unlawfully [3][4] - Pfizer intends to pursue all legal avenues to enforce its rights under the existing agreement with Metsera [4] Group 3: Metsera's Board Decision - Metsera's Board previously rejected Novo Nordisk's proposal due to various risks associated with its deal structure, favoring Pfizer for its certainty and expected timeline [5] Group 4: Market Reaction - Following the news, Metsera's stock rose by 21.03% to $63.19, while Novo Nordisk's stock fell by 2.31% to $50.19 [5]